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Background: Mortality among critically ill patients with candidemia is very high. We sought to determine whether
the choice of initial antifungal therapy is associated with survival among these patients, using need for mechanical
ventilatory support as a marker of critical illness.
Methods: Cohort analysis of outcomes among mechanically ventilated patients with candidemia from the 24 North
American academic medical centers contributing to the Prospective Antifungal Therapy (PATH) Alliance registry.
Patients were included if they received either fluconazole or an echinocandin as initial monotherapy.
Results: Of 5272 patients in the PATH registry at the time of data abstraction, 1014 were ventilated and
concomitantly had candidemia, with 689 eligible for analysis. 28-day survival was higher among the 374 patients
treated initially with fluconazole than among the 315 treated with an echinocandin (66% versus 51%, P < .001).
Initial fluconazole therapy remained associated with improved survival after adjusting for non-treatment factors in
the overall population (hazard ratio .75, 95% CI .59–.96), and also among patients with albicans infection (hazard
ratio .62, 95% CI .44–.88). While not statistically significant, fluconazole appeared to be associated with higher
mortality among patients infected with glabrata (HR 1.13, 95% CI .70–1.84).
Conclusions: Among ventilated patients with candidemia, those receiving fluconazole as initial monotherapy were
significantly more likely to survive than those treated with an echinocandin. This difference persisted after
adjustment for non-treatment factors.
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Candidemia is a major cause of nosocomial bloodstream
infection in the United States [1,2], particularly among
intensive care unit (ICU) patients [3,4]. Increasing attrib-
utable mortality from candidemia has prompted research
into the role of early diagnosis and treatment in improv-
ing outcomes [3,5,6].
Rapid initiation of appropriate antibiotic therapy has re-
sulted in better survival among patients with septic shock
and ventilator-associated pneumonia [7-9]. Similarly, im-
proved outcomes have been reported with early treatment
of suspected fungal infections, though often patients are* Correspondence: mmorris2@med.miami.edu
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reproduction in any medium, provided the orstarted on therapy before speciation [10-12]. Thus, the
epidemiology of candidemia may impact the choice of ini-
tial therapy. Non-albicans species comprise approximately
half of Candida bloodstream infections, with increasing
isolation of species less susceptible to fluconazole [13].
The introduction of the echinocandins has expanded
the options available for the treatment of Candida infec-
tions in the critically ill. Whether these newer medications
are preferable to fluconazole as initial antifungal therapy
in the ICU remains unresolved. While recent guidelines
recommend the use of echinocandins for moderately se-
vere to severely ill patients with candidemia [14], previous
comparisons of azoles and echinocandins have included
only limited populations of critically ill patients [15-17].
Perhaps more importantly, controlled trials have not
evaluated initial therapy; enrollment criteria permitted
up to 48 hours of antifungal therapy before initiation of
study drug [16,18,19]. Recent critiques of the guidelineLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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address actual clinical circumstance [20,21].
A large controlled trial of initial antifungal therapy for
critically ill patients with candidemia promises to be
extremely challenging logistically. The need for therapy is
often unrecognized until Candida is identified in culture.
Once fungemia is recognized, evidence suggests therapy
should be started as quickly as possible, leaving little time
for trial related activities such as consent and ran-
domization. Absent the more definitive data from such a
trial, a cohort study of critically ill patients treated with
either fluconazole or an echinocandin as initial therapy
should inform current practice and point the way forward
for further investigations. We therefore analyzed the epi-
demiology and outcomes of patients included in a large,
multicenter mycosis registry who required mechanical
ventilatory support, had candidemia, and received initial
monotherapy of fluconazole or an echinocandin.
Methods
Data collection
Data were extracted from the Prospective Antifungal
Therapy (PATH) Alliance registry, created in 2004 to
collect information about patients with invasive fungal
infections at 24 centers in the United States and Canada
[22]. Qualifying patients entered in the PATH registry
through September 17, 2008 were followed for survival
through 28 days. The Human Subject Research Office of
the University of Miami Miller School of Medicine
reviewed and approved the protocol (HSRO 20060202).
We submitted a proposal to the registry sponsors to re-
view all candidemia cases entered in the registry that
were reported in mechanically ventilated patients, and we
were granted permission to analyze this subgroup of the
PATH database.
Patients were considered critically ill if mechanically ven-
tilated at the time the initial positive culture was obtained.
Critically ill patients were included in the analysis if they
were diagnosed with candidemia and received initial anti-
fungal monotherapy with either an echinocandin or flucon-
azole from zero to six days after the index culture was
obtained. Patients were excluded if they had a previous or
concurrent fungal infection recorded in the PATH registry.
Data regarding delay between index culture and initiation
of therapy, whether therapy was started before cultures
were known to be positive (defined as empiric therapy), an-
tifungal agents used, Candida species found on the index
culture, and antifungal agents received in the month prior
to the index culture were recorded. The PATH database
does not fully distinguish prior non-directed antifungal ex-
posure from empiric therapy, counting antifungal courses
initiated before identification of candidemia and continued
to confirmation of infection as both directed therapy and
prior exposure.Possible risk factors for candidemia or death were re-
corded including: malignancies; diabetes mellitus; corticos-
teroid use, or receipt of other immunosuppressive medica-
tions or total body irradiation in the preceding month, or
either (any immunosuppressive therapy); neutropenia,
(fewer than 500 neutrophils/mm3) within the preceding
month; post-operative status; solid organ transplant recipi-
ent; HIV infection; serum creatinine > 2 mg/dL, receiving
renal replacement therapy, or either (any renal dysfunc-
tion); and transaminitis (alanine aminotransferase or aspar-
tate aminotransferase > 100 U/L), total bilirubin > 3 mg/dL,
or either (any liver disease). Patients were followed for up
to 12 weeks following the initial positive culture.
Statistical analysis
Population characteristics were compared across initial
therapy using Fisher’s exact test, the χ2 test, and t tests or
Wilcoxon’s test, as appropriate for data type and distri-
bution. The principal outcome, survival through 28 days
within initial antifungal therapy groups, was evaluated
using the log-rank test. Day zero was the first day antifun-
gal therapy was administered. P < .05 was considered a sig-
nificant difference between treatment groups.
Propensity for use of echinocandins as initial therapy
was modeled using logistic regression. Candidate predic-
tors included all demographic and risk factors, time
delay between obtaining the index culture and starting
antifungal therapy, and whether therapy was started
empirically. Candida species was not considered, as
it would not typically be known when candidemia is
first recognized and treatment prescribed. Variables
were chosen using forward stepwise selection, requiring
P < .20 to enter or remain in the model. The discrimin-
ation capacity of the propensity model was tested using
the C statistic.
The relationships of individual factors with initial anti-
fungal therapy were assessed using proportional hazards
models. The hazard ratio associated with fluconazole as
initial therapy was calculated in the subpopulations with
and without each risk factor in univariate models, and
the P value for inclusion of the interaction term between
each risk factor and initial therapy calculated from the
corresponding bivariate models for the entire population.
A treatment independent risk term (TIRT) was calcu-
lated for each patient. A proportional hazards model of
survival through 28 days was created using as candidate
predictors all demographic and risk factors, time delay
between index culture and antifungal therapy initiation,
whether therapy was started empirically, and propensity
for echinocandin use. Variables were chosen for inclusion
using forward stepwise selection with switching, requiring
P < .20 to enter or remain in the model. The TIRT was cal-
culated for each patient from this model (the coefficient
for TIRT being unity in a univariate model).
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fluconazole across the entire population was calculated
by including initial therapy and TIRT in a bivariate pro-
portional hazards model. Because the PATH registry does
not clearly distinguish prior from empiric antifungal ther-
apy, this analysis was repeated for subpopulations defined
by receipt of prior or empiric therapy to ensure robustness
of results. Similar analyses were carried out for the sub-
populations infected with each Candida species after de-
termining that TIRT appropriately described treatment
independent risk for each subpopulation.
Results and discussion
Population characteristics
The PATH registry included 1516 mechanically venti-
lated patients. Of these, 810 had candidemia as their first
PATH registered infection and received initial therapyFigure 1 PATH study patient distribution and study enrollment for anwithin zero to six days of the index blood culture. An
antifungal other than an echinocandin or fluconazole
was initially administered to 93 patients, and another 28
received both an echinocandin and fluconazole on day
zero. Thus, 689 patients qualified for this analysis, 315
(46%) treated initially with an echinocandin and 374
(54%) with fluconazole (Figure 1).
Patients given an echinocandin as initial therapy were
more likely to have received immunosuppressive therapies
in the preceding month and to have renal dysfunction at
the time of diagnosis than patients treated with flucona-
zole (P < .001 for each) (Table 1). Hematologic malignan-
cies were rare but more common among patients treated
with echinocandins [17 (5%) echinocandin patients and 8
(2%) fluconazole patients], as was recent neutropenia [20
(6%) echinocandin patients and 2 (1%) fluconazole pa-
tients]. The overall malignancy rate was the same in bothalysis.
Table 1 Patient characteristics by initial therapy
Characteristic Echinocandin Fluconazole P
(n = 315) (n = 374)
Male 168 (53%) 198 (53%) .94
Age 58 ± 17 56 ± 21 .17
Immunosuppressive therapy
within 30 days
189 (60%) 155 (41%) <.001
Corticosteroids 184 (58%) 153 (41%) <.001
Nonsteroid immunosuppressive
therapy
43 (14%) 25 (7%) .003
Renal injury (serum
creatinine > 2 mg/dL or dialysis)
146 (46%) 124 (33%) <.001
Dialysis (chronic or acute) 101 (32%) 77 (21%) <.001
Any malignancy 49 (16%) 61 (16%) .83
Hematologic malignancy 17 (5%) 8 (2%) .025
Solid tumor 34 (11%) 55 (15%) .14
Neutropenia within in the
preceding 30 days
20 (6%) 2 (1%) <.001
Diabetes mellitus 139 (44%) 134 (36%) .029
Abnormal hepatic function 123 (39%) 120 (32%) .066
Transaminitis 84 (27%) 81 (22%) .13
Hyperbilirubinemia 87 (28%) 79 (21%) .050
Solid organ transplant 31 (10%) 16 (4%) .004
HIV seropositive 6 (2%) 5 (1%) .56
Surgical patient 119 (38%) 164 (44%) .12
Values are n (%) or mean ± SD.
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more likely to have had a solid organ transplant, diabetes
mellitus, and hyperbilirubinemia.Antifungal management and Candida species
Use within the preceding month of an antifungal agent as
prophylaxis (or possibly for a suspected but ultimately
unconfirmed infection) was common, and higher among
patients initially prescribed an echinocandin for theirTable 2 Patient characteristics by initial therapy
Characteristic Echinocandin Fluconazole P
(n = 315) (n = 374)
Antifungal exposure in
preceding 30 days
164 (52%) 143 (38%) <.001
Triazole exposure 92 (29%) 127 (34%) .19
Echinocandin exposure 90 (29%) 15 (4%) <.001
Empiric therapy 47 (15%) 52 (14%) .74
Delay between culture
and treatment, days
2.5 ± 1.4 2.2 ± 1.4 .033
Months since PATH registry
opened
26 ± 11 23 ± 12 <.001
Initial therapy changed by day 2 35 (11%) 90 (24%) <.001
Initial therapy changed by day 6 98 (31%) 121 (32%) .74
Values are n (%) or mean ± SD.index infection than among those prescribed fluconazole
[164 (52%) versus 143 (38%), P < .001] (Table 2). Patients
previously given an echinocandin were unlikely to receive
fluconazole for the index infection. The likelihood of receiv-
ing empiric treatment did not differ with choice of therapy,
occurring in 47 (15%) of the echinocandin patients and 52
(14%) of the fluconazole patients (P = .74). Echinocandin
patients were on average entered into the PATH registry
three months later than fluconazole patients (P < .001).
In 334 (48%) cases Candida albicans was the sole cause
of candidemia. Candida glabrata was the only species iso-
lated in 175 (25%) cases, parapsilosis in 85 (12%), tropica-
lis in 51 (7%), and krusei in 10 (1%). Thirty-four (5%)
patients had either another or multiple species isolated.
Of the patients with glabrata, 113 (65%) had received an-
tifungal therapy either as prophylaxis or as empiric ther-
apy, compared to 133 (40%) of albicans infected patients
and no more than 45% of patients infected with any other
species (P < .001). Choice of initial therapy varied with
species (P < .001), with 210 (63%) of albicans infected pa-
tients initially prescribed fluconazole and 110 (63%) of
glabrata infected patients initially prescribed echinocan-
dins (Table 3).
The initial antifungal was changed or supplemented
within two days more often among fluconazole than
echinocandin patients [90 (24%) and 35 (11%) patients
respectively, P < .001], but within six days of starting
therapy changes or supplementation rates were almost
identical. Changes to initial fluconazole treatment oc-
curred most commonly one day after identification of
candidemia, and on that day almost equally among pa-
tients infected with any species other than albicans, sug-
gesting that early results of testing for albicans infection
motivated the change (Figure 2). In contrast, changes to
initial echinocandin regimens typically were made three
to four days after identification of candidemia.
The propensity model for using an echinocandin as
initial therapy included nine parameters. Increasing age,
immunosuppressive therapy, dialysis, neutropenia, and
previous echinocandin use all predicted a higher likeli-
hood of echinocandin use, while empiric treatment, pre-
vious corticosteroid use, and having a non-hematologicTable 3 Initial therapy by species
Species Echinocandin Fluconazole
(n = 315) (n = 374)
Albicans 124 (37%) 210 (63%)
Glabrata 110 (63%) 65 (37%)
Krusei 6 (60%) 4 (40%)
Parapsilosis 31 (37%) 54 (64%)
Tropicalis 24 (47%) 27 (53%)
Other species or mixed infection 20 (59%) 14 (41%)
Values are n (%).
Figure 2 Frequency of changes from initial therapy by day since candidemia confirmation, by initial regimen (fluconazole in upper
graph, echinocandin in lower graph) and mycology. Thick bars show patterns for albicans and aggregated non-albicans cases, thin bars individual
non-albicans species (for species with at least 20 cases). Heights of bars represent the percent of patients within each category (treatment and species)
switched on a given day.
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use also rose over time. The model’s discrimination was
C = .75.
Initial therapy and survival
Survival through 28 days was lower among patients initially
treated with echinocandins than among those treated with
fluconazole (51% and 66% respectively, P < .001) (Figure 3).
Univariate proportional hazards analysis yielded a hazardratio of .61 (.48–.78) associated with fluconazole as ini-
tial therapy.
Initial therapy with fluconazole remained a predictor
of better outcome irrespective of whether therapy was
changed early (within two days of starting therapy) or
continued for longer periods. Among the 35 of 315 pa-
tients initially treated with an echinocandin who had an-
tifungal therapy changed 28 day survival was 51%, no
different than that of patients initially treated with an
Figure 3 Survival through 28 days by initial therapy for candidemia.
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two days. In contrast, among the 90 patients initially
treated with fluconazole whose therapy was changed
within the first two days, 28 day survival was 61%. Survival
to 28 days among patients who received fluconazole alone
for more than two days was 68%. Proportional hazards
modeling found no significant interaction between initial
therapy choice, whether or not therapy was changed within
two days, and survival (P = .79 for interaction). Initial ther-
apy with fluconazole remained a predictor of better out-
come, irrespective of whether therapy was changed early.
The point estimate for the hazard ratio associated with
use of fluconazole as initial therapy was 1.37 (.31–6.13)
among the 22 patients who had been neutropenic. For
all other risk factors, point estimates of the hazard ratio
associated with fluconazole use were less than one in
both subpopulations with and without each risk factor
(Figure 4). An interaction (P = .010) was noted between
malignancy and fluconazole therapy: hazard ratio .70
(.54–.92) among the patients without malignancy, and
.32 (.19–.56) among the 110 with malignancy.
The TIRT included 11 parameters. Increasing age, im-
munosuppressive therapy, liver disease, elevated biliru-
bin, dialysis, neutropenia, non-hematologic malignancy,
and male gender were associated with increased risk of
death, while delay between culture and treatment initi-
ation, surgical status, and having a solid organ transplant
were associated with reduced risk. Propensity for echi-
nocandin use did not enter the model. TIRT predicted
mortality rates ranged from 10% in the lowest decile ofrisk to nearly 80% in the highest decile (Figure 5), with
C statistic of 0.74. The TIRT anticipated a 6% absolute
difference in 28 day survival favoring the group treated
initially with fluconazole.
In the entire study population, initial therapy was inde-
pendently associated with risk of death when accounting
for other risks using the TIRT in a bivariate proportional
hazards model: fluconazole had a hazard ratio of .75
(.59–.96). The coefficient for TIRT, .969 (.809–1.129),
remained close to unity.
The association between initial therapy choice for can-
didemia and survival changed little depending upon
whether patients received prior or empiric antifungal
therapy. Adjusting for other risk factors using the TIRT,
the hazard ratio associated with fluconazole was .73
(.52–1.02) among patients who had not previously re-
ceived antifungals, and .79 (.55–1.13) among those who
had received prior (including empiric) therapy, .78 (.50–
1.21) among those documented as having received prior
but no empiric therapy, and .84 (.45–1.57) among those
who received empiric therapy.
Initial fluconazole therapy remained a significant pre-
dictor of survival when accounting for other risks using the
TIRT among patients with albicans candidemia, with haz-
ard ratio .62 (.44–.88). For other species the hazard ratios
associated with initial therapy did not differ significantly
from unity, but point estimates suggested increased risk of
death with fluconazole therapy among patients with glab-
rata and krusei infection, and decreased risk among pa-
tients with parapsilosis and tropicalis infection (Figure 6).
Figure 4 Summary analysis of treatment outcomes associated with the absence or presence of specific candidemia risk factors.
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Candidemia is life-threatening in critically ill patients,
with a crude 30-day mortality of approximately 50%
[4,23-25]. In our cohort, initial therapy with fluconazole
























Figure 5 TIRT performance over deciles of risk. Patients were grouped
for each treatment group is displayed for each decile of risk. The line demoechinocandins. Rapid initiation of antifungal therapy im-
proves survival, but previous studies have not addressed
initial treatment [10-12,26]. PATH records actual clinical
practice, includes a greater number of critically ill patients
than other candidemia studies, and does not exclude6 7 8 9 10 
T Decile 
into deciles by TIRT-predicted risk for death by day 28. Actual mortality
nstrates the TIRT-predicted risk for the entire decile.
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Figure 6 Outcome of initial therapy by Candida species.
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morbidity. This registry thus may provide a truer picture
of the treated population than do many controlled trials.
Our findings may impact treatment decisions for these pa-
tients, particularly as they are inconsistent with recently
promulgated recommendations for therapy [14,27].
Uniquely, our analysis focuses on initial therapy, con-
sidered key for other severe infections. For example, in-
adequate initial antimicrobial therapy for bloodstream
infections and pneumonia is strongly associated with in-
creased hospital mortality [7,9]. Controlled trials of can-
didemia treatment have allowed as much as 48 hours of
non-study antifungal therapy [16,18,19]. Re-analysis of
these trials cannot address this crucial early treatment
period [28].
In clinical practice initial antifungal therapy cannot
usually be directed by species. Germ tube analysis, a rapid
test widely available during PATH registration, only deter-
mines whether a Candida is albicans. That day 1 was the
most frequent day for switching from initial fluconazole
therapy suggests changes were often made when it was
determined that the pathogen was not albicans, since re-
sponse to antifungal therapy could not have been reason-
ably assessed by that time. Consistent with this rationale,
patients infected with parapsilosis were as likely to be
switched from fluconazole as those with glabrata in the
first days of therapy. Newer tests, such as peptide nucleic
acid-fluorescence in situ hybridization (PNA-FISH), have
accelerated speciation in some centers, but the majority of
patients with candidemia are started on therapy before the
species is determined [29].
Initial therapy often differs from later tailored therapy,
particularly if resistance is present. Some forms of re-
sistance may not be relevant during early therapy; forexample, fluconazole resistance in Candida glabrata is
mediated by inducible enzymes that may not be expressed
early in the course of treatment [30]. Intrinsic Candida re-
sistance to fluconazole is relatively rare, found in 9–15%
of glabrata [9] (25% of registry cases), and in krusei
(fewer than 2% of cases), therefore impacting fewer than
5% of patients with candidemia overall [13]. Resistance
to both echinocandins and fluconazole has been re-
ported from a large international survey of clinical Can-
dida isolates [31].
Initial therapy for suspected or proven candidemia in
the ICU may be chosen based upon severity of illness,
sensitivities of probable infecting species, physician habit
and other factors. Published guidelines, based largely on
expert opinion, have expressed a preference for an echi-
nocandin over fluconazole as initial therapy for moder-
ately to severely ill patients, a criterion satisfied by all of
the patients included in our study [4,14]. The apparent
inferiority of echinocandins as initial therapy in the
PATH population stands in contrast to this recommen-
dation; if the guideline is correct, the impact of unmeas-
ured variables in our study would have to be sufficient
to not only account for the observed survival difference
but to reverse it.
Whether initial antifungal therapy was changed in the
first days of treatment or not did not influence the asso-
ciation of therapy choice and survival. If fluconazole
therapy were indeed inferior to echinocandin therapy,
one would expect patients started and continued on
echinocandins to have been more likely to survive than
patients started on fluconazole and then only later
switched to another agent (whether because of clinical
failure or laboratory findings). This was not the case
however: patients started on fluconazole and then
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were more likely to survive than those initially treated
with an echinocandin.
While the propensity score accounts for some of the
differences that might have led to use of an echinocan-
din instead of fluconazole, it almost certainly does not
encompass all factors contributing to prescribing deci-
sions. Beyond this, we believe uniformity of practice is
unlikely over the diversity of sites and prescribers. Sub-
set analyses also demonstrate that the PATH registry’s
possible conflation of empiric and previous prophylac-
tic antifungal use cannot account for the differences
in survival.
It is unlikely that differences in underlying disease ac-
count for the survival differences we observed between
treatment groups. Studies of the critically ill have consist-
ently found that, once ongoing physiology is accounted
for, underlying diseases impact short-term mortality only
when present in their most severe forms [32-34]. Data re-
garding such conditions were captured by PATH and in-
cluded in regression models.
The PATH registry captures data on several organ dys-
functions associated with mortality in critically ill septic
patients and typically incorporated into acuity models: re-
spiratory (present in all patients included in this analysis),
renal, and hepatic. These data were included in the devel-
opment process for the TIRT and propensity models. The
performance of the TIRT was comparable to that of other
composite risk models, such as APACHE II, when used to
stratify patients with severe infections [35,36].
An obvious potential confounder not recorded in the
PATH database was presence or absence of shock. The
addition of vital signs data to those incorporated in the
TIRT is unlikely to appreciably improve stratification of
these patients [36]. All patients studied satisfied severe
sepsis criteria, with candidemia and at least one organ
failure. Cardiovascular dysfunction in this setting is gen-
erally associated with a further attributable mortality risk
of approximately 5–7% [37]. This could account for
some of the difference in outcome we observed if almost
all patients with hypotension were treated initially with
echinocandins, and almost all patients treated with echi-
nocandins were hypotensive when therapy was started.
This is highly improbable, since prescribing habits are
seldom so uniform across centers, particular in the ab-
sence of compelling pre-existing data. A recent large
cross-sectional study found virtually identical vasopres-
sor use and severity of illness scores among candidemia
patients treated with fluconazole or an echinocandin [38].
Our results differ from the prospective, randomized
trial in patients with candidemia and invasive candidiasis
comparing fluconazole and anidulafungin, which demon-
strated improved clinical and microbiological response in
the echinocandin arm [19]. In a retrospective analysis ofthe moderately severe to severely ill patient subset from
this trial the trend toward improved global response
persisted [39]. A recent patient-level review of candidemia
trials reported improved clinical outcomes in patients re-
ceiving an echinocandin. In subgroup analysis, this benefit
was restricted to the less sick half of the analyzed popula-
tion [28]. The validity of this published analysis has also
been questioned, as restriction to the more current studies
eliminates the reported benefit of echinocandin therapy
[40]. Because of study design, the effect of initial therapy
cannot be addressed.
Conclusions
Our study represents the largest investigation of initial
antifungal therapy for candidemia in mechanically venti-
lated patients. The results favor fluconazole, contrasting
with several recent recommendations and guidelines
reflecting expert opinion but only limited clinical data.
Despite the challenges, we believe a large, controlled cli-
nical trial comparing fluconazole and an echinocandin
as initial antifungal therapy for candidemia in the critic-
ally ill is warranted.
Key messages
– Randomized controlled trials of therapy for
candidemia in the critically ill have not evaluated
initial therapy, considered critically important in the
treatment of other types of infections.
– In a large, multicenter registry of fungal infections,
mortality was lower among mechanically ventilated
patients initially treated with fluconazole than
among those treated with an echinocandin. These
mortality differences persisted after adjusting for
severity of acute and chronic illness.
– Currently published guidelines lean toward the use
of echinocandins in the treatment of candidemia in
critically ill patients. A large, randomized trial is
justified to identify the optimal initial management
of this population.
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